A Retrospective Analysis of Pain Etiology in Middle-Aged Patients with Peripheral Neuropathy
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Demography
3.2. Laboratory Analysis
4. Discussion
4.1. Epidemiology
4.2. Neuroinflammation
4.3. CSF Markers
4.4. Other Laboratory Markers
4.5. Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- DiAntonio, A. Axon Degeneration: Mechanistic Insights Lead To Therapeutic Opportunities for the Prevention and Treatment of Peripheral Neuropathy. Pain 2019, 160, S17–S22. [Google Scholar] [CrossRef] [PubMed]
- Alessandro, L.; Pastor Rueda, J.M.; Wilken, M.; Querol, L.; Marrodán, M.; Acosta, J.N.; Rivero, A.; Barroso, F.; Farez, M.F. Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. J. Peripher. Nerv. Syst. 2018, 23, 154–158. [Google Scholar] [CrossRef] [PubMed]
- Hughes, R.A.C. Clinical review Regular review Peripheral neuropathy. BMJ 2002, 324, 466–469. [Google Scholar] [CrossRef] [PubMed]
- Sommer, C.; Geber, C.; Young, P.; Forst, R.; Birklein, F.; Schoser, B. Polyneuropathies-etiology, diagnosis, and treatment options. Dtsch. Arztebl. Int. 2018, 115, 83–90. [Google Scholar]
- Chkheidze, R.; Pytel, P. What every neuropathologist needs to know: Peripheral nerve biopsy. J. Neuropathol. Exp. Neurol. 2020, 79, 355–364. [Google Scholar] [CrossRef] [PubMed]
- Barohn, R.J.; Amato, A.A. Pattern-recognition approach to neuropathy and neuronopathy. Neurol. Clin. 2013, 31, 343–361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Patel, K.; Horak, H.; Tiryaki, E. Diabetic neuropathies. Muscle Nerve 2021, 63, 22–30. [Google Scholar] [CrossRef]
- Devigili, G.; Tugnoli, V.; Penza, P.; Camozzi, F.; Lombardi, R.; Melli, G.; Broglio, L.; Granieri, E.; Lauria, G. The diagnostic criteria for small fibre neuropathy: From symptoms to neuropathology. Brain 2008, 131, 1912–1925. [Google Scholar] [CrossRef] [Green Version]
- Lehmann, H.C.; Wunderlich, G.; Fink, G.R.; Sommer, C. Diagnosis of peripheral neuropathy. Neurol. Res. Pract. 2020, 2, 1–7. [Google Scholar] [CrossRef]
- Coraci, D.; Loreti, C.; Fusco, A.; Giovannini, S.; Padua, L. Peripheral neuropathies seen by ultrasound: A literature analysis through lexical evaluation, geographical assessment and graph theory. Brain Sci. 2021, 11, 113. [Google Scholar] [CrossRef]
- Lauria, G.; Hsieh, S.T.; Johansson, O.; Kennedy, W.R.; Leger, J.M.; Mellgren, S.I.; Nolano, M.; Merkies, I.S.J.; Polydefkis, M.; Smith, A.G.; et al. European federation of neurological societies/peripheral nerve society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. report of a joint task force of the european fe-deration of neurological societies and the peripheral ne. Eur. J. Neurol. 2010, 17, e44–e49. [Google Scholar] [CrossRef]
- Haroutounian, S.; Todorovic, M.S.; Leinders, M.; Campagnolo, M.; Gewandter, J.S.; Dworkin, R.H.; Freeman, R. Diagnostic criteria for idiopathic small fiber neuropathy: A systematic review. Muscle Nerve 2020, 63, 170–177. [Google Scholar] [CrossRef]
- Ratté, S.; Prescott, S.A. Afferent hyperexcitability in neuropathic pain and the inconvenient truth about its degeneracy. Curr. Opin. Neurobiol. 2016, 36, 31–37. [Google Scholar] [CrossRef]
- Ochoa, J.L.; Campero, M.; Serra, J.; Bostock, H. Hyperexcitable polymodal and insensitive nociceptors in painful human neuropathy. Muscle Nerve 2005, 32, 459–472. [Google Scholar] [CrossRef] [PubMed]
- Terkelsen, A.J.; Karlsson, P.; Lauria, G.; Freeman, R.; Finnerup, N.B.; Jensen, T.S. The diagnostic challenge of small fibre neuropathy: Clinical presentations, evaluations, and causes. Lancet Neurol. 2017, 16, 934–944. [Google Scholar] [CrossRef]
- Voortman, M.; Fritz, D.; Vogels, O.J.M.; Eftimov, F.; Van De Beek, D.; Brouwer, M.C.; Drent, M. Small fiber neuropathy: A disabling and underrecognized syndrome. Curr. Opin. Pulm. Med. 2017, 23, 447–457. [Google Scholar] [CrossRef] [Green Version]
- Lauria, G.; Merkies, I.S.J.; Faber, C.G. Small fibre neuropathy. Curr. Opin. Neurol. 2012, 25, 542–549. [Google Scholar] [CrossRef] [PubMed]
- Sène, D. Small fiber neuropathy: Diagnosis, causes, and treatment. Jt. Bone Spine 2018, 85, 553–559. [Google Scholar] [CrossRef] [PubMed]
- Hovaguimian, A.; Gibbons, C.H. Diagnosis and treatment of pain in small-fiber neuropathy. Curr. Pain Headache Rep. 2011, 15, 193–200. [Google Scholar] [CrossRef] [Green Version]
- Devigili, G.; Rinaldo, S.; Lombardi, R.; Cazzato, D.; Marchi, M.; Salvi, E.; Eleopra, R.; Lauria, G. Diagnostic criteria for small fibre neuropathy in clinical practice and research. Brain 2019, 142, 3728–3736. [Google Scholar] [CrossRef] [PubMed]
- Meacham, K.; Shepherd, A.; Mohapatra, D.P.; Haroutounian, S. Neuropathic Pain: Central vs. Peripheral Mechanisms. Curr. Pain Headache Rep. 2017, 21, 28. [Google Scholar] [CrossRef]
- De Freitas, M.R.G. Infectious neuropathy. Curr. Opin. Neurol. 2007, 20, 548–552. [Google Scholar] [CrossRef]
- Mellion, M.; Gilchrist, J.M.; De La Monte, S. Alcohol-related peripheral neuropathy: Nutritional, toxic, or both? Muscle Nerve 2011, 43, 309–316. [Google Scholar] [CrossRef]
- Manji, H. Toxic neuropathy. Curr. Opin. Neurol. 2011, 24, 484–490. [Google Scholar] [CrossRef] [PubMed]
- Stino, A.M.; Smith, A.G. Peripheral neuropathy in prediabetes and the metabolic syndrome. J. Diabetes Investig. 2017, 8, 646–655. [Google Scholar] [CrossRef] [PubMed]
- Callaghan, B.C.; Price, R.S.; Feldman, E.L. Diagnostic and Therapeutic Advances: Distal Symmetric Polyneuropathy. JAMA 2015, 314, 2172–2181. [Google Scholar] [CrossRef] [PubMed]
- Visser, N.A.; Notermans, N.C.; Linssen, R.S.N.; Van Den Berg, L.H.; Vrancken, A.F.J.E. Incidence of polyneuropathy in Utrecht, the Netherlands. Neurology 2015, 84, 259–264. [Google Scholar] [CrossRef]
- Hoffman, E.M.; Staff, N.P.; Robb, J.M.; St. Sauver, J.L.; Dyck, P.J.; Klein, C.J. Impairments and comorbidities of polyneuropathy revealed by population-based analyses. Neurology 2015, 84, 1644–1651. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sloan, G.; Shillo, P.; Selvarajah, D.; Wu, J.; Wilkinson, I.D.; Tracey, I.; Anand, P.; Tesfaye, S. A new look at painful diabetic neuropathy. Diabetes Res. Clin. Pract. 2018, 144, 177–191. [Google Scholar] [CrossRef]
- Feldman, E.L.; Callaghan, B.C.; Pop-Busui, R.; Zochodne, D.W.; Wright, D.E.; Bennett, D.L.; Bril, V.; Russell, J.W.; Viswanathan, V. Diabetic neuropathy. Nat. Rev. Dis. Prim. 2019, 5, 41. [Google Scholar] [CrossRef]
- Gwathmey, K.G.; Grogan, J. Nutritional neuropathies. Muscle Nerve 2020, 62, 13–29. [Google Scholar] [CrossRef]
- Bouhassira, D.; Lantéri-Minet, M.; Attal, N.; Laurent, B.; Touboul, C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008, 136, 380–387. [Google Scholar] [CrossRef] [Green Version]
- Katz, J.; Rosenbloom, B.N.; Fashler, S. Chronic pain, psychopathology, and DSM-5 somatic symptom disorder. Can. J. Psychiatry 2015, 60, 160–167. [Google Scholar] [CrossRef] [Green Version]
- Geneen, L.J.; Moore, R.A.; Clarke, C.; Martin, D.; Colvin, L.A.; Smith, B.H. Physical activity and exercise for chronic pain in adults: An overview of Cochrane Reviews. Cochrane Database Syst. Rev. 2017, 1, CD011279. [Google Scholar] [CrossRef] [Green Version]
- Treede, R.D.; Rief, W.; Barke, A.; Aziz, Q.; Bennett, M.; Benoliel, R.; Cohen, M.; Evers, S.; Finnerup, N.; First, M.B.; et al. A classification of chronic pain for ICD-11. Pain 2015, 156, 1003–1007. [Google Scholar] [CrossRef] [Green Version]
- Baron, R.; Binder, A.; Wasner, G. Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010, 9, 807–819. [Google Scholar] [CrossRef]
- Szok, D.; Tajti, J.; Nyári, A.; Vécsei, L. Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behav. Neurol. 2019, 2019, 8685954. [Google Scholar] [CrossRef]
- Barbosa, F.; Delerue Matos, A.; Voss, G.; Costa, P. Spousal Care and Pain among the Population Aged 65 Years and Older: A European Analysis. Front. Med. 2021, 8, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Giovannini, S.; van der Roest, H.G.; Carfì, A.; Finne-Soveri, H.; Garms-Homolová, V.; Declercq, A.; Jónsson, P.V.; van Hout, H.; Vetrano, D.L.; Gravina, E.M.; et al. Polypharmacy in Home Care in Europe: Cross-Sectional Data from the IBenC Study. Drugs Aging 2018, 35, 145–152. [Google Scholar] [CrossRef]
- Domenichiello, A.F.; Ramsden, C.E. The silent epidemic of chronic pain in older adults. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2019, 93, 284–290. [Google Scholar] [CrossRef] [PubMed]
- Hanewinckel, R.; van Oijen, M.; Ikram, M.A.; van Doorn, P.A. The epidemiology and risk factors of chronic polyneuropathy. Eur. J. Epidemiol. 2016, 31, 5–20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hanewinckel, R.; Drenthen, J.; Verlinden, V.J.A.; Darweesh, S.K.L.; Van Der Geest, J.N.; Hofman, A.; Van Doorn, P.A.; Ikram, M.A. Polyneuropathy relates to impairment in daily activities, worse gait, and fall-related injuries. Neurology 2017, 89, 76–83. [Google Scholar] [CrossRef]
- Van Hecke, O.; Austin, S.K.; Khan, R.A.; Smith, B.H.; Torrance, N. Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain 2014, 155, 654–662. [Google Scholar] [CrossRef]
- Torrance, N.; Ferguson, J.A.; Afolabi, E.; Bennett, M.I.; Serpell, M.G.; Dunn, K.M.; Smith, B.H. Neuropathic pain in the community: More under-treated than refractory? Pain 2013, 154, 690–699. [Google Scholar] [CrossRef] [Green Version]
- Smith, B.H.; Torrance, N. Epidemiology of neuropathic pain and its impact on quality of life. Curr. Pain Headache Rep. 2012, 16, 191–198. [Google Scholar] [CrossRef] [PubMed]
- Udall, M.; Kudel, I.; Cappelleri, J.C.; Sadosky, A.; King-Concialdi, K.; Parsons, B.; Hlavacek, P.; Hopps, M.; Salomon, P.A.; Dibonaventura, M.D.; et al. Epidemiology of physician-diagnosed neuropathic pain in Brazil. J. Pain Res. 2019, 12, 243–253. [Google Scholar] [CrossRef] [Green Version]
- Ji, R.; Chamessian, A.; Zhang, Y. Pain regulation by non-neuronal cells and inflammation. Science 2016, 354, 572–577. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sommer, C.; Leinders, M.; Üçeyler, N. Inflammation in the pathophysiology of neuropathic pain. Pain 2018, 159, 595–602. [Google Scholar] [CrossRef]
- Ziegler, D.; Strom, A.; Bönhof, G.J.; Kannenberg, J.M.; Heier, M.; Rathmann, W.; Peters, A.; Meisinger, C.; Roden, M.; Thorand, B.; et al. Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy. BMJ Open Diabetes Res. Care 2019, 7, 1–9. [Google Scholar] [CrossRef]
- Shieh, A.; Epeldegui, M.; Karlamangla, A.S.; Greendale, G.A. Gut permeability, inflammation, and bone density across the menopause transition. JCI Insight 2020, 5, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Au, A.; Feher, A.; McPhee, L.; Jessa, A.; Oh, S.; Einstein, G. Estrogens, inflammation and cognition. Front. Neuroendocrinol. 2016, 40, 87–100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Buford, T.W. (Dis)Trust your gut: The gut microbiome in age-related inflammation, health, and disease. Microbiome 2017, 5, 80. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khoonsari, P.E.; Ossipova, E.; Lengqvist, J.; Svensson, C.I.; Kosek, E.; Kadetoff, D.; Jakobsson, P.J.; Kultima, K.; Lampa, J. The human CSF pain proteome. J. Proteom. 2019, 190, 67–76. [Google Scholar] [CrossRef] [PubMed]
- Guldbrandsen, A.; Vethe, H.; Farag, Y.; Oveland, E.; Garberg, H.; Berle, M.; Myhr, K.M.; Opsahl, J.A.; Barsnes, H.; Berven, F.S. In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). Mol. Cell. Proteom. 2014, 13, 3152–3163. [Google Scholar] [CrossRef] [Green Version]
- Palada, V.; Ahmed, A.S.; Freyhult, E.; Hugo, A.; Kultima, K.; Svensson, C.I.; Kosek, E. Elevated inflammatory proteins in cerebrospinal fluid from patients with painful knee osteoarthritis are associated with reduced symptom severity. J. Neuroimmunol. 2020, 349, 577391. [Google Scholar] [CrossRef]
- Verma, V.; Sheikh, Z.; Ahmed, A.S. Nociception and role of immune system in pain. Acta Neurol. Belg. 2015, 115, 213–220. [Google Scholar] [CrossRef]
- Issac, T.; Soundarya, S.; Christopher, R.; Chandra, S. Vitamin B12 deficiency: An important reversible co-morbidity in neuropsychiatric manifestations. Indian J. Psychol. Med. 2015, 37, 26–29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Devalia, V.; Hamilton, M.S.; Molloy, A.M. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br. J. Haematol. 2014, 166, 496–513. [Google Scholar] [CrossRef]
- England, J.D.; Gronseth, G.S.; Franklin, G.; Carter, G.T.; Kinsella, L.J.; Cohen, J.A.; Asbury, A.K.; Szigeti, K.; Lupski, J.R.; Latov, N.; et al. Evaluation of distal symmetric polyneuropathy: The role of laboratory and genetic testing (an evidence-based review). Muscle Nerve 2009, 39, 116–125. [Google Scholar] [CrossRef]
- Allen, L.H. How common is vitamin B-12 deficiency? Am. J. Clin. Nutr. 2009, 89, 693–696. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.H.; Yan, F.; Zhang, W.B.; Ye, G.; Zheng, Y.Y.; Zhang, X.H.; Shao, F.Y. An investigation of vitamin B12 deficiency in elderly inpatients in neurology department. Neurosci. Bull. 2009, 25, 209–215. [Google Scholar] [CrossRef] [Green Version]
- Mold, J.W.; Vesely, S.K.; Keyl, B.A.; Schenk, J.B.; Roberts, M. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J. Am. Board Fam. Pract. 2004, 17, 309–318. [Google Scholar] [CrossRef] [Green Version]
- Buesing, S.; Costa, M.; Schilling, J.M.; Moeller-Bertram, T. Vitamin B12 as a treatment for pain. Pain Physician 2019, 22, E45–E52. [Google Scholar] [CrossRef] [PubMed]
- Jayabalan, B.; Low, L.L. Vitamin B supplementation for diabetic peripheral neuropathy. Singap. Med. J. 2016, 57, 55–59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, M.; Han, W.; Hu, S.; Xu, H. Methylcobalamin: A potential vitamin of pain killer. Neural Plast. 2013, 2013. [Google Scholar] [CrossRef]
- Bharathi, G.; Jayaramayya, K.; Balasubramanian, V.; Vellingiri, B. The potential role of rhythmic entrainment and music therapy intervention for individuals with autism spectrum disorders. J. Exerc. Rehabil. 2019, 15, 180–186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, J.Y.; Wu, Y.H.; Liu, S.J.; Lin, Y.S.; Lu, P.H. Vitamin B12 for herpetic neuralgia: A meta-analysis of randomised controlled trials. Complement. Ther. Med. 2018, 41, 277–282. [Google Scholar] [CrossRef] [PubMed]
- Julian, T.; Syeed, R.; Glascow, N.; Angelopoulou, E.; Zis, P. B12 as a treatment for peripheral neuropathic pain: A systematic review. Nutrients 2020, 12, 2221. [Google Scholar] [CrossRef]
- Gylfadottir, S.S.; Itani, M.; Krøigård, T.; Kristensen, A.G.; Christensen, D.H.; Nicolaisen, S.K.; Karlsson, P.; Callaghan, B.C.; Bennett, D.L.; Andersen, H.; et al. Diagnosis and prevalence of diabetic polyneuropathy: A cross-sectional study of Danish patients with type 2 diabetes. Eur. J. Neurol. 2020, 27, 2575–2585. [Google Scholar] [CrossRef]
- Hébert, H.L.; Veluchamy, A.; Torrance, N.; Smith, B.H. Risk factors for neuropathic pain in diabetes mellitus. Pain 2017, 158, 560–568. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Feldman, E.L.; Nave, K.A.; Jensen, T.S.; Bennett, D.L.H. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron 2017, 93, 1296–1313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Persson, A.K.; Hoeijmakers, J.G.J.; Estacion, M.; Black, J.A.; Waxman, S.G. Sodium Channels, Mitochondria, and Axonal Degeneration in Peripheral Neuropathy. Trends Mol. Med. 2016, 22, 377–390. [Google Scholar] [CrossRef] [PubMed]
- Lauria, G.; Ziegler, D.; Malik, R.; Merkies, I.S.J.; Waxman, S.G.; Faber, C.G. The Role of Sodium Channels in Painful Diabetic and Idiopathic Neuropathy. Curr. Diabetes Rep. 2014, 14, 538. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Gender (Female) n = 63 (50.81%) | Gender (Male) n = 61 (49.19%) | p Value |
---|---|---|---|
Age of diagnosis, years | 56.00 (±14.99) | 57.35 (±14.48) | >0.05 |
Place of residence | |||
Village | 13 (35.14%) | 24 (64.86%) | <0.05 |
City | 50 (54.47%) | 37 (42.53%) | |
Type of nerve fiber involvement * | |||
Sensory | 0 (0.00%) | 3 (100.00%) | >0.05 |
Motor | 9 (50.00%) | 9 (50.00%) | |
Sensorimotor | 48 (52.17%) | 44 (47.83%) | |
Distribution | |||
Symmetric | 39 (43.82%) | 50 (56.18%) | >0.05 |
Asymmetric | 17 (54.84%) | 14 (45.16%) | |
Asymmetric with the involvement of the cranial nerves | 1 (25.00%) | 3 (75.00%) | |
Type of the damage * | |||
Axonal | 15 (53.57%) | 13 (46.43%) | >0.05 |
Demyelinating | 25 (43.10%) | 33 (56.90%) | |
Mixed | 17 (62.96%) | 10 (37.04%) | |
Evolution/Severity | |||
Inflammatory | 21 (50.00%) | 21 (50.00%) | >0.05 |
Subacute | 11 (40.74%) | 16 (59.26%) | |
Small fiber neuropathy | 6 (54.55%) | 5 (45.45%) | |
Chronic | 23 (57.50%) | 17 (42.50%) | |
Acute | 1 (50.00%) | 1 (50.00%) | |
Hereditary | 1 (50.00%) | 1 (50.00%) |
Characteristic | No Pain n = 73 (58.87%) | Pain n = 51 (41.13%) | p Value | Logistic Regression | |
---|---|---|---|---|---|
OR (95% CI) | p Value | ||||
Gender | |||||
Female | 36 (57.14%) | 27 (42.86%) | >0.05 | 1 | |
Male | 37 (60.66%) | 24 (39.34%) | 0.86 (0.42–1.78) | >0.05 | |
Place of residence | |||||
Village | 26 (70.27%) | 11 (29.73%) | >0.05 | 1 | |
City | 47 (54.02%) | 40 (45.98%) | 2.01 (0.88–4.62) | >0.05 | |
Type of nerve fiber involvement * | |||||
Sensorimotor | 53 (57.61%) | 39 (42.39%) | <0.05 | 1 | |
Sensory | 1 (33.33%) | 2 (66.67%) | NA | - | |
Motor | 18 (100.00%) | 0 (0.00%) | NA | - | |
Distribution | |||||
Symmetric | 53 (67.95%) | 25 (32.05%) | >0.05 | 1 | |
Asymmetric | 16 (51.61%) | 15 (48.39%) | 1.99 (0.84–4.69) | >0.05 | |
Asymmetric with the involvement of cranial nerves | 3 (75.00%) | 1 (25.00%) | 0.84 (0.26–2.72) | >0.05 | |
Type of the damage * | |||||
Axonal | 14 (50.00%) | 14 (50.00%) | >0.05 | 1 | |
Demyelinating | 41 (70.69%) | 17 (29.31%) | 0.41 (0.16–1.07) | >0.05 | |
Mixed | 17 (62.96%) | 10 (37.04%) | 0.77 (0.44–1.33) | >0.05 | |
Evolution/Severity | |||||
Inflammatory | 31 (73.81%) | 11 (26.19%) | <0.001 | 1 | |
Subacute | 13 (48.15%) | 14 (51.85%) | 3.03 (1.07–8.59) | <0.05 | |
Small fiber Neuropathy | 1 (9.09%) | 10 (90.91%) | 5.31 (1.75–16.11) | <0.01 | |
Chronic | 28 (70.00%) | 12 (30.00%) | 1.06 (0.77–1.48) | >0.05 | |
Acute | 0 (0.00%) | 2 (100.00%) | - | - | |
Hereditary | 0 (0.00%) | 2 (100.00%) | - | - |
Characteristic | Sensory Type n = 3 (2.65%) | Motor Type n = 18 (15.93%) | Sensorimotor Type n = 92 (81.42%) | p Value | Axonal n = 28 (24.78%) | Demyelinating n = 58 (51.33%) | Mixed n = 27 (23.89%) | p Value |
---|---|---|---|---|---|---|---|---|
Age of diagnosis | 51.33 (±17.67) | 52.61 (±12.14) | 59.17 (±13.83) | >0.05 | 58.25 (±12.08) | 57.50 (±14.30) | 58.48 (±14.81) | >0.05 |
WBC × 1000/μL | 5.65 (±3.63) | 6.25 (±1.89) | 6.49 (±2.06) | >0.05 | 6.19 (±2.32) | 6.49 (±2.03) | 6.54 (±1.88) | >0.05 |
CRP mg/L | - | 8.04 (±17.13) | 9.63 (±21.38) | >0.05 | 12.35 (±27.08) | 8.64 (±14.46) | 8.03 (±24.73) | >0.05 |
ESR | - | 11.44 (±10.33) | 22.42 (±25.37) | >0.05 | 23.21 (±28.85) | 18.93 (±20.16) | 22.38 (±24.86) | >0.05 |
Vit. B12 pg/mL | - | 503.67 (±285.20) | 1262.34 (±2588.59) | >0.05 | 1079.46 (±2071.99) | 1332.57 (±2832.33) | 523.90 (±270.46) | >0.05 |
Potassium (K+) mmol/L | 4.83 (±0.29) | 4.36 (±0.42) | 4.30 (±0.40) | >0.05 | 4.27 (±0.42) | 4.33 (±0.36) | 4.36 (±0.49) | >0.05 |
Sodium (Na+) mmol/L | 140.67 (±3.06) | 142.78 (±1.90) * | 141.36 (±2.64) * | <0.05 | 142.26 (±2.31) | 141.53 (±2.54) | 140.96 (±2.84) | >0.05 |
Glucose mg/dL | 113.67 (±20.21) | 103.86 (±11.99) | 100.91 (±18.30) | >0.05 | 110.92 (±27.13) | 98.10 (±10.40) | 100.08 (±14.77) | >0.05 |
Protein in CSF mg/dL | - | 81.60 (±119.00) | 55.14 (±59.56) | >0.05 | 40.39 (±14.75) | 75.18 (±93.07) | 38.60 (±15.34) | >0.05 |
Cytosis in CSF cells/μL | - | 2.20 (±1.69) | 4.16 (±8.54) | >0.05 | 2.92 (±3.30) | 5.00 (±10.20) | 1.93 (±1.58) | >0.05 |
Characteristic | Gender (Female) n = 63 (50.81%) | Gender (Male) n = 61 (49.19%) | p Value | No Pain n = 73 (58.87%) | Pain n = 51 (41.13%) | p Value |
---|---|---|---|---|---|---|
Age of diagnosis | 56.00 (±14.99) | 57.35 (±14.48) | >0.05 | 57.10 (±16.82) | 56.40 (±13.14) | >0.05 |
WBC × 1000/μL | 6.34 (±2.00) | 6.65 (±2.12) | >0.05 | 6.64 (±2.06) | 6.38 (±2.07) | >0.05 |
CRP mg/L | 11.26 (±24.55) | 7.21 (±11.78) | >0.05 | 12.12 (±20.91) | 7.70 (±19.55) | >0.05 |
ESR | 32.50 (±28.47) | 12.28 (±14.33) | <0.001 | 21.59 (±22.80) | 19.31 (±23.58) | >0.05 |
Vit. B12 pg/mL | 1369.31 (±2819.98) | 877.46 (±1519.454) | >0.05 | 1414.50 (±2184.85) | 921.81 (±2384.84) | >0.05 |
Potassium (K+) mmol/L | 4.34 (±0.44) | 4.31 (±0.38) | >0.05 | 4.30 (±0.46) | 4.34 (±0.37) | >0.05 |
Sodium (Na+) mmol/L | 141.68 (±2.71) | 141.53 (±2.43) | >0.05 | 141.38 (±2.47) | 141.77 (±2.63) | >0.05 |
Glucose mg/dL | 102.38 (±19.60) | 100.29 (±13.22) | >0.05 | 100.51 (±14.04) | 102.08 (±18.85) | >0.05 |
Protein in CSF mg/dL | 52.42 (±67.66) | 64.68 (±71.74) | >0.05 | 57.42 (±31.26) | 58.51 (±85.54) | >0.05 |
Cytosis in CSF cells/μL | 2.92 (±4.71) | 4.74 (±9.84) | >0.05 | 5.00 (±10.71) | 2.98 (±4.48) | >0.05 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Szewczyk, A.K.; Jamroz-Wiśniewska, A.; Rejdak, K. A Retrospective Analysis of Pain Etiology in Middle-Aged Patients with Peripheral Neuropathy. Medicina 2021, 57, 787. https://doi.org/10.3390/medicina57080787
Szewczyk AK, Jamroz-Wiśniewska A, Rejdak K. A Retrospective Analysis of Pain Etiology in Middle-Aged Patients with Peripheral Neuropathy. Medicina. 2021; 57(8):787. https://doi.org/10.3390/medicina57080787
Chicago/Turabian StyleSzewczyk, Anna K., Anna Jamroz-Wiśniewska, and Konrad Rejdak. 2021. "A Retrospective Analysis of Pain Etiology in Middle-Aged Patients with Peripheral Neuropathy" Medicina 57, no. 8: 787. https://doi.org/10.3390/medicina57080787